Orr Inbar, CEO and co-founder of QuantHealth, unpacks the growing frustration over drug prices and the misperceptions fueling distrust in the pharmaceutical industry. With clinical trials now more ...

In 2023 the FDA published guidance on rare diseases. The guidance recognises that many rare diseases are serious conditions ...

On July 22, 2025, the US Food and Drug Administration (FDA) started accepting applications to participate in the Commissioner’s National ...

AI was supposed to boost drug discovery, but progress has stalled. Learn why the hype hasn’t delivered and what needs to change for AI to make an impact.

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of ...

A recent meta-analysis reveals no link between pathologic complete response and long-term survival in rectal cancer, challenging its use as a surrogate endpoint.

The 2024 approvals included significant milestones in the biosimilar sector, with the FDA granting approval for the first biosimilar of Stelara, Wezlana and the first denosumab biosimilars, Wyost and ...

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its proprietary CDH17-targeting antibody-drug conjugate (ADC), 7MW4911, has received ...

Elutia Inc. (Nasdaq: ELUT) ('Elutia” or the 'Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Michelle LeRoux Williams, Chief Scientific Officer, has been awarded ...

As a longtime Washington Post reporter and an author of 10 books, he held corporate America accountable for safe ...

Advances in instruments and tools, as well as focused collaborations, improve accuracy and extend the range of applications.

Cutting off assistance to Colombia completely won’t change Gustavo Petro, but it will make the United States less safe.